Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease.

Ultragenyx (RARE) Pharmaceutical announced new data demonstrating treatment with UX111 AAV gene therapy led to a statistically significant improvement in the Bayley-IIIi raw scores for the ...

One of the most notable additions is Gemini's ability to generate graphs based on spreadsheet data. Users can instruct the AI to create visual representations, such as a chart of segments by ...

The launch of a low-cost Artificial Intelligence (AI) model from China has sent tremors around the globe — wiping $1 trillion off stock markets and raising fears around free speech. DeepSeek is a new ...

Mike Ashley has scored a victory in a data protection dispute against HMRC following a £13m row with the taxman. In a ruling on Monday, the High Court said the tax body had wrongly withheld ...

discusses positive safety and efficacy data for NT-501 for macular telangiectasia type 2. NT-501 (revakinagene taroretcel, Neurotech Pharmaceuticals), an encapsulated cell therapy, was well ...

Last August, Tris Pharma commenced two pivotal Phase III studies, ALLEVIATE-1 and ALLEVIATE-2, to assess the therapy. "Tris Pharma reports positive data from Phase III acute pain therapy trial ...